Risk of Mild Cognitive Impairment and Its Relation to Anticholinergics Revealed Within Screening in a Community Pharmacy

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Bratislava Medical Journal

• Publication date

  2025-11-08

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s44411-025-00422-z
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the Potential Pharmacotherapeutic Risk in Hospitalized Geriatric Patients

  2025cited by this paper
• Study protocol for identification of patients with risk of cognitive impairment in advanced pharmaceutical care in a community pharmacy

  2025influential reference
• Systemic medications and dementia risk: a systematic umbrella review

  2025cited by this paper
• Medication Adherence and Intervention Strategies: Why Should We Care

  2025cited by this paper
• Advanced pharmaceutical services in community pharmacies

  2025influential reference
• Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.

  2024cited by this paper
• Drug-Induced Cognitive Impairment

  2024cited by this paper
• Medication reconciliation and seamless care led by clinical pharmacists in Slovenia: a national reimbursed program ensuring safe and effective transition of care

  2024cited by this paper
• Selecting a Brief Cognitive Screening Test Based on Patient Profile: It Is Never Too Early to Start

  2024cited by this paper
• Polypharmacy and potentially inappropriate prescribing of benzodiazepines in older nursing home residents

  2024cited by this paper
• Assessment of potentially inappropriate medication use among geriatric outpatients in the Slovak Republic

  2023cited by this paper
• Clinical pharmacist interventions in the transition of care in a mental health hospital: case reports focused on the medication reconciliation process

  2023cited by this paper
• Risk factors of cognitive impairment in elderly people in the Republic of Kazakhstan.

  2023cited by this paper
• Cardiovascular disease risk models and dementia or cognitive decline: a systematic review

  2023cited by this paper
• Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes

  2023cited by this paper
• American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults

  2023cited by this paper
• Usefulness of Community Pharmacy for Early Detection of Cognitive Impairment in Older People Using the IQ-CODE Questionnaire

  2023cited by this paper
• Identification of a Link between Suspected Metabolic Syndrome and Cognitive Impairment within Pharmaceutical Care in Adults over 75 Years of Age

  2023influential reference
• Longitudinal associations of anticholinergic medications on cognition and possible mitigating role of physical activity

  2023cited by this paper
• Social support, positive caregiving experience, and caregiver burden in informal caregivers of older adults with dementia

  2023cited by this paper
• Pharmacists as accessible health care providers: quantifying the opportunity

  2022cited by this paper
• Short cognitive screening in elderlies as a part of advanced pharmaceutical care in Slovak community pharmacies - The pilot study KOGNIMET-SK

  2022cited by this paper
• The anticholinergic burden: from research to practice

  2022cited by this paper
• CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the PREVENT-Dementia study

  2022cited by this paper
• Age‐related changes in cerebrovascular health and their effects on neural function and cognition: A comprehensive review

  2021cited by this paper
• Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System

  2021cited by this paper
• RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study

  2021cited by this paper
• Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia.

  2021cited by this paper
• Correlation between cardiovascular risk factors and cognitive decline

  2021cited by this paper
• Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review

  2020cited by this paper
• Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

  2020cited by this paper
• Distinctive Effects of Aerobic and Resistance Exercise Modes on Neurocognitive and Biochemical Changes in Individuals with Mild Cognitive Impairment.

  2019cited by this paper
• Genetic predisposition, modifiable risk factor profile and long-term dementia risk in the general population

  2019cited by this paper
• The Impact of Pharmacist Interventions on Quality Use of Medicines, Quality of Life, and Health Outcomes in People with Dementia and/or Cognitive Impairment: A Systematic Review

  2019cited by this paper
• Integrating assessment of cognitive status in elderly cardiovascular care

  2019cited by this paper
• Decision Tree for Early Detection of Cognitive Impairment by Community Pharmacists

  2018cited by this paper
• Metabolic Syndrome and cognitive decline in the elderly: A systematic review

  2018influential reference
• Correlation Coefficients: Appropriate Use and Interpretation

  2018cited by this paper
• Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson’s Disease and Cross-Cultural Comparison

  2018cited by this paper
• A systematic review of medication non-adherence in persons with dementia or cognitive impairment

  2017cited by this paper
• Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease

  2016cited by this paper
• The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial.

  2016cited by this paper
• Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA).

  2016cited by this paper
• The CAIDE Dementia Risk Score App: The development of an evidence-based mobile application to predict the risk of dementia

  2015influential reference
• Are area-level and individual-level socioeconomic factors associated with self-rated health in adult urban citizens? Evidence from Slovak and Dutch cities

  2015cited by this paper
• Association between metabolic syndrome and mild cognitive impairment and its age difference in a chinese community elderly population

  2015cited by this paper
• Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review

  2015influential reference
• Potential for primary prevention of Alzheimer's disease: an analysis of population-based data.

  2014cited by this paper
• Normal cognitive aging.

  2013cited by this paper
• Cognitive memory screening and referral program in community pharmacies in the United States

  2013cited by this paper
• The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.

  2012cited by this paper
• Cardiovascular Disease Risk Factors and Cognition in the Elderly

  2011cited by this paper
• Reviews

  2011cited by this paper
• Selective review of cognitive aging

  2010cited by this paper
• Impact of anticholinergics on the aging brain: a review and practical application

  2008influential reference
• Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.

  2006cited by this paper
• The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

  2005cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004cited by this paper
• Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization.

  1994cited by this paper

• No citing papers are available for this paper.